The precise effects of CD34 þ cell dose on the outcome of allogeneic transplantation for aplastic anaemia (AA) are not known. Previous studies have used the total mononuclear cell count to quantify stem cell dose. We evaluated the effects of CD34 þ cell dose on the clinical and haematological end points of transplantation. The transplant variables and outcome parameters on 46 patients with acquired AA were assessed by comparing low vs high CD34 þ cell doses. Infusion of less than 2 Â 10 6 /kg of CD34 þ cells was associated with an increased incidence of graft failures (P ¼ 0.03), higher incidence of bacterial infections (P ¼ 0.006) and a delay in the engraftment of neutrophils (P ¼ 0.046). The latter was found to be an effect of stem cell source (non-PBSC) rather than the CD34 þ count. Other parameters, such as plt engraftment (P ¼ 0.63), red cell (P ¼ 0.94) and plt (P ¼ 0.31) transfusion independence, chimerism, acute and chronic GVHD (P ¼ 1.0) and OS (P ¼ 0.57), were not significantly influenced by the CD34 þ cell dose. These findings are different to the published studies on the relevance of CD34 þ cell dose in allogeneic transplantation for haematological cancers.
Introduction
CD34 is a type 1 transmembrane protein expressed on haemopoietic stem cells with the capacity to repopulate BM for all lineages. 1 In clinical practice, CD34 þ expression is considered to be the equivalent of a pluripotent haemopoietic stem cell with the ability of self-renewal.
The number of infused CD34 þ cells is known to be a significant predictor of the outcome of autologous and Allo-SCT for haematological malignancies. In 2000, Siena et al. reviewed the relevance of CD34 þ cell dose for all forms of haemopoietic transplantation for malignancies. 2 They suggested that the optimal CD34 þ dose for successful autologous transplantation was 8 Â 10 6 /kg and the dose for allogeneic transplants was unclear. In the same year, Singhal et al. recommended a CD34 þ dose of 2 Â 10 6 /kg as the minimum threshold for allogeneic sibling blood or marrow SCT. 3 Two years later, Bittencourt et al. concluded that a CD34 þ dose of 3 Â 10 6 /kg was optimal for allogeneic BMT in terms of faster engraftment, decreased treatment-related mortality and increased OS. 4 Allo-SCT is a potentially curative therapeutic option for aplastic anaemia (AA). All the above-mentioned studies were predominantly, if not exclusively, on patients with haematological malignancies. Compared to leukaemia, lymphoma and myeloma, AA is a rare haematological disorder for which many patients are treated without transplantation. Consequently, very little literature is available on the implications of CD34 þ cell dose for allo-SCT in AA patients.
The stem cell dose for AA has traditionally been reported as the number of total nucleated cells and not the actual CD34 þ cell count. 5, 6 The importance of infusing at least 3 Â 10 8 /kg of total nucleated cells has been well recognized. A significant increase in the incidence of graft failure and a reduction in OS have been shown at doses below this threshold. [5] [6] [7] We evaluated the influence of CD34 þ cell dose on the outcome of transplantation in 46 patients with acquired AA. The effects on haematological engraftment, graft failure, chimerism, transfusion dependency, GVHD and OS were compared by classifying patients into those who received a high cell dose and those who received a low cell dose.
Methods

Study setting
The study was a retrospective evaluation of acquired AA patients transplanted using HLA-identical sibling or HLAmatched unrelated donors at St George's Hospital in London over a continuous 10-year period. The study plan was discussed with the hospital ethics committee and approval was obtained for the non-interventional study, limited to analysis of retrospective data. The patients received standard treatment and confidentiality was ensured at all the stages of analysis.
Relevant data were extracted from a combination of clinical notes, electronic patient record, blood bank records and the transplantation database.
Patients and eligibility
Between January 1998 and August 2008, 56 patients with BM failure syndromes had allogeneic transplants. Consecutive non-probability sampling was done to recruit patients to the study population. Ten patients with congenital marrow failure (Fanconi anaemia, Schwachman Diamond syndrome) were excluded from the analysis. For patients who had multiple transplants, only the first episode was considered for the study. After exclusions, the final sample population consisted of 46 patients. The median follow-up of survivors was 4.68 years, with a range of 0.57-11.08 years.
Study definitions 'Severe' AA was defined as marrow cellularity of o25% with any two of the following: neutrophils o0.5 Â 10 9 /l, plts o20 Â 10 9 /l and reticulocyte count o20 Â 10 9 /l. The patients were categorized as 'very severe' if, in addition, the neutrophil count was o0.2 Â 10 9 /l. 8, 9 The dose of infused stem cells was classified as 'low' (o3.4 Â 10 6 /kg) or 'high' (X3.4 Â 10 6 /kg) based on the median CD34 þ cell count across the study population.
The first of 3 consecutive days of ANC of 40.5 Â 10 9 /l was assigned as the point of 'neutrophil engraftment'. 'Platelet engraftment' was considered as the first of 3 consecutive days of plt count of 420 Â 10 9 /l without plt transfusion requirement for 7 preceding days.
'Red cell transfusion independence' was defined as the earliest point at which the patient remained untransfused with packed red cells for 30 consecutive days and continued to maintain Hb X80 g/l unsupported thereafter. 'Platelet transfusion independence' corresponded to the earliest point at which the patient remained untransfused with plts for 7 consecutive days. The threshold for plt transfusion was a plt count of o10 Â 10 9 /l, provided the patients were clinically well and had no bleeding manifestations other than bruises.
'Graft failure' was defined as either the absence of haematological recovery in patients surviving X21 days after transplantation (primary graft failure) or recovery followed by recurrent pancytopenia (late graft failure) with a hypocellular marrow in the absence of severe GVHD. 10 Whole blood and cell lineage-specific chimerism was analysed on recipient marrow and blood for transplants since 2003. A semi-quantitative PCR-based method involving amplification of genes containing short tandem repeat sequences was performed. Whole blood donor cell percentage X99% was defined as 'complete donor chimerism' and o99% as 'mixed chimerism'. The latter was subclassified into 'stable mixed chimerism' when donor cells were persistently 470% and 'increasing mixed chimerism' when donor cells fell to p70%.
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'GVHD' was diagnosed on clinical grounds along with histological confirmation where possible and graded according to standard criteria. 12, 13 GVHD was classified as 'acute' if the onset was within 100 days of SCT and 'chronic' beyond this period.
Collection, storage and infusion of CD34 þ cells Stem cells were harvested from donor marrow or venous blood after G-CSF mobilization. CD34 þ cell quantification was performed using the standard technique of immunofluorescence flow cytometry.
14 The immunophenotyping section of our laboratory is validated every 2 months by mandatory participation in the UK National External Quality Assessment Service and the CD34 þ cell count results have shown consistency and comparability to other similar laboratories within the country. CD34 þ cells were infused on the same day or cryopreserved with DMSO, stored in liquid nitrogen and thawed at 37 1C before infusion at a later date. b Three patients did not engraft, one patient engrafted but died on day +102 and one patient engrafted but rejected on day +88, and were hence excluded.
Conditioning, immunosuppression and supportive care
Conditioning regimen varied according to the age of the patient, year of transplant, type of donor, previous treatment and comorbidities (Table 1) . For a majority of children and for most of the recent HLA-matched unrelated donor adult transplants, alemtuzumab (MabCampath)-based conditioning regimen was used. This included a combination of 10 mg (0.2 mg/kg for children) alemtuzumab for 5 days and 50 mg/kg CY for 4 days. For those patients receiving fludarabine-based conditioning regimens, CY dose was 300 mg/m 2 for 4 days with 30 mg/m 2 fludarabine for 4 days. The majority of patients conditioned without alemtuzumab received a combination of 50 mg/kg CY for 4 days and antithymocyte globulin (ATG; Genzyme, Cambridge, MA, USA) 1.5 vials per 10 kg for 3 days (Table 1) . Post-transplant immunosuppression consisted of 5 mg/kg ciclosporin, starting on day À1 and continued for 12 months, with tapering from 9 months. Levels were measured using mouse monoclonal Ab assays at least weekly and maintained within the 200-300 ng/ml range with close monitoring of renal function. Short-course MTX was given at a dose of 15 mg/m 2 on day þ 1, followed by 10 mg/m 2 on days þ 3, þ 6 and þ 11. MTX was omitted for patients who received campath-based conditioning.
CSFs were not routinely used to help with engraftment. G-CSF use was restricted to selected patients who were neutropenic and septic. For Pneumocystis carinii prophylaxis, 300 mg pentamidine was nebulised monthly until achievement of a neutrophil count of 41 Â 10 9 /l and a plt count of 475 Â 10 9 /l. After this, the prophylaxis was switched to 480 mg cotrimoxazole orally twice daily for 3 days per week, until 12 months after transplant. Itraconazole 2.5 mg/kg twice daily and 200 mg aciclovir thrice daily were administered orally for prevention of fungal and viral infections.
Outcome measures and statistical analysis
The clinical end points were graft failure, acute GVHD, chronic GVHD and OS. Haematological outcome was assessed in terms of neutrophil engraftment, plt engraftment, red cell transfusion independence, plt transfusion independence and chimerism. The patients were classified into low and high CD34 þ dose subgroups and the end points were compared.
Mann-Whitney test was used for comparison of mean ranks on continuous variables for the two patient subgroups. The differences between categorical variables were assessed with chi-square or Fisher's exact test as appropriate. Kaplan-Meier estimator with log-rank test was used to evaluate the cumulative incidences between the two subgroups. Univariate Cox regression was applied to determine the predictive effect of individual variables for haematological outcomes. The risk of graft failure was assessed using logistic regression. Covariates with Pp0.1 were added to the model for multivariate analysis.
All statistical tests were two sided and Po0.05 was considered significant. Data were analysed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) statistical software.
Results
For the whole study population, the median CD34 þ cell dose was 3.4 Â 10 6 /kg (range 0.5-10.1). The baseline characteristics of the 46 patients are shown in Table 1 . There were no major differences between the CD34 þ cell dose subgroups with respect to age, gender, severity of AA, median disease duration, type of donor Time (days) Figure 1 The effect of CD34 þ dose on engraftment of neutrophils and plts.
CD34 þ dose in aplastic anaemia transplants MS Islam et al or conditioning regimen (Table 2) . A significant difference in CD34 þ cell count was noted between the subgroups with regard to cell source, with higher counts from donors who had PBSC harvest. Concurrent CD34 þ and total nucleated cell counts were available only for a minority (7 of 46) of patients. Spearman's correlation test performed on these patients showed a positive linear relationship between the two (P ¼ 0.014; correlation coefficient r ¼ 0.85).
Initial analysis using a cutoff CD34 þ cell count of 3.4 Â 10 6 /kg The cutoff CD34 þ cell dose of 3.4 Â 10 6 /kg did not influence the time to engraft neutrophils (P ¼ 0.25) or plts (P ¼ 0.34) (Figures 1a and c) . No difference was observed between the two groups in the time to achieve red cell (P ¼ 0.65) or plt (P ¼ 0.83) transfusion independence (Figures 2a and c) .
Grades II-IV of acute GVHD were observed in only 3 of 46 (6.5%) patients. Extensive chronic GVHD was encountered in only 2 of 46 (4.3%) patients. The CD34 þ cell dose was not observed to affect the risk for acute (P ¼ 1.0) or chronic (P ¼ 1.0) forms of GVHD ( Table 2) .
The data on chimerism were available for only 22 patients, all of whom had transplants in or after 2003. Increasing mixed chimerism was observed in only 2 and 1 patients in the low and high cell dose subgroups, respectively, and hence statistical tests could not be performed.
In all, eight patients had graft failure, of which three were primary failures. The median (1.68 Â 10 6 /kg) and range (0.5-5.1 Â 10 6 /kg) of CD34 þ cell dose was lower for patients who had graft failure compared with the median (3.75 Â 10 6 /kg) and range (1.0-10.1 Â 10 6 /kg) of CD34 þ dose for those who did not have graft failure, but without statistical significance (P ¼ 0.09). Five patients in the low CD34 þ group and three in the high CD34 þ group suffered graft failure, but the difference was not significant (P ¼ 0.70).
In total, five patients died on days þ 10 (Candidal sepsis), þ 13 (bacterial sepsis), þ 102 (invasive aspergillosis), þ 427 (cytomegalovirus pneumonia) and þ 705 (bronchiolitis obliterans), respectively. No patient was lost to follow-up. OS was not different (P ¼ 0.69) between the two patient groups (Figure 3a) . Subsequent analysis using cutoff CD34 þ cell count of 2.0 Â 10 6 /kg As the median CD34 þ level of 3.4 Â 10 6 /kg did not influence any of the clinical or haematological outcome measurements, we evaluated values above and below this count. It was found that the cutoff count, which showed a significant influence, was much lower. The population was re-analysed by dividing into tertiles. The highest CD34 þ Figure 2 The effect of CD34 þ dose on red cell and plt transfusion independence. /kg and the lowest CD34 þ count of the middle tertile was 2.15 Â 10 6 /kg. The latter value did not show a significant effect on the outcome (data not shown). Hence, the patients were re-classified into low and high CD34 þ subgroups based on a CD34 þ threshold dose of 2 Â 10 6 /kg. Two patients had CD34 þ counts of exactly 2 Â 10 6 /kg and were included under the high cell dose group.
Using this lower CD34 þ threshold, statistical significance was found for the time to neutrophil engraftment (P ¼ 0.046; Figure 1b ) and graft failure (P ¼ 0.03; Table 2 ). All other parameters, such as plt engraftment (P ¼ 0.63; Figure 1d ), red cell transfusion independence (P ¼ 0.94; Figure 2b ), plt transfusion independence (P ¼ 0.31; Figure 2d ), acute and chronic GVHD, chimerism (Table 2) and OS (P ¼ 0.57; Figure 3b ) remained unaffected by the CD34 þ cell dose. The patients who received a lower CD34 þ cell dose were significantly more likely to have post-transplant bacterial infections (P ¼ 0.006), whereas no difference was noted between the low and high CD34 þ cell subgroups with respect to viral or fungal infections (Table 3) .
Multivariate analysis showed PBSC source to be associated with a faster neutrophil engraftment (P ¼ 0.008) and CD34 þ cell dose of X2.0 Â 10 6 /kg to be associated with a lower incidence of graft failure (P ¼ 0.03) ( Table 4) . 
P=0.57 Figure 3 The effect of CD34 þ dose on OS. 
Discussion
Unlike SCT for malignancies, the influence of CD34 þ cell dose on specific outcome parameters has not been evaluated in AA transplants. Two studies have mentioned the median CD34 þ cell count but have not analysed its significance with respect to outcome, as this was not their primary study objective. 15, 16 Some researchers have considered the total mononuclear cell count as a variable with potential influence on graft failure and OS. 5, 6, [17] [18] [19] Other published studies to date have not included CD34 þ cell dose in their analysis. [20] [21] [22] [23] [24] We used the median CD34 þ count to define the cutoff to ensure an even distribution of patients in the low-and high-dose arms.
Neither Kaplan-Meier analysis (with log-rank test) nor Cox regression using the median CD34 þ cell count showed any statistically significant influence on outcome. Using a lower cutoff of 2.0 Â 10 6 /kg, a significant difference was identified in the cumulative incidence of neutrophil engraftment between the two cell dose subgroups and a lower risk of graft failure for the higher cell dose subgroup. However, on multivariate analysis, it was observed that in patients with faster neutrophil engraftment, the effect was mainly as a result of the CD34 þ cell source (PBSC) rather than the actual CD34 þ count. These findings are in contrast to SCT for haematological malignancies, in which direct correlation has been identified between infused CD34 þ cell count and a variety of end points. In an analysis of 212 patients who underwent BMT mainly for malignancies (176 patients; 83%), Bittencourt et al. showed that a CD34 þ cell dose of 43 Â 10 6 /kg was associated with faster recovery of the neutrophil, plt, red cell, monocyte and lymphocyte counts, higher transplantation-related mortality and lesser OS. 4 Similar results were observed with other studies on haematological cancers, including a review of the long-term transplant data from Seattle. 25 The reasons behind the favourable influence of PBSC source rather than actual CD34 þ cell count on neutrophil recovery are not clear from our study. However, it may be because of the fact that our lower CD34 þ cell dose subgroup had only 13 patients, which compromises statistical power.
In total, 3 out of 46 patients (6.5%) had severe acute GVHD and 2 out of 46 patients (4.3%) had extensive chronic GVHD. These figures are considerably lower when compared with most previous reports on allogeneic transplantation for AA. [15] [16] [17] [18] [19] Because of the small number of patients with GVHD, it is not possible to conclude from our study whether a high stem cell dose increases its risk. For haematological disorders in general, investigators have found a greater risk of chronic GVHD with PBSC transplant in the setting of a large CD34 þ cell dose. [25] [26] [27] This may be due to increased type-2 cytokines and IL-10-producing monocytes, which together result in late immune dysregulation. 28 The notable reduction in the incidence of severe forms of GVHD could partly be attributed to the extensive use of alemtuzumab for conditioning in the majority of our patients. The superiority of the alemtuzumab-based conditioning for AA transplants in terms of decreased incidence of acute and chronic GVHD has been brought out by previous work from our centre as well as other studies from Toronto and Houston. [29] [30] [31] [32] Most of our patients (36 out of 46; 78.3%) had donor marrow as the stem cell source, as recommended by the national guideline. 33 This is another likely explanation for the low incidence of GVHD in our analysis.
In the low CD34 þ cell dose subgroup, a significantly higher proportion of patients had post-transplant bacterial infections. This was found to be independent of the time to neutrophil engraftment. There was no significant difference between the two subgroups with respect to viral and fungal infections after allo-SCT. This is in contrast to the similar study on haematological malignancies by Bittencourt et al., which showed a higher incidence of fungal, but not bacterial or viral posttransplant infections. 4 In conclusion, our study shows that an infusion of less than 2 Â 10 6 /kg of CD34 þ cells increases the risk of graft failure. Delayed neutrophil engraftment in patients whose stem cell dose is below this threshold was noted to be an effect of cell source rather than actual CD34 þ number. Bacterial infections were significantly more common in patients who received lower CD34 þ cell dose. The CD34 þ cell count did not affect the time to engraft plts or achieve transfusion independence. High CD34 þ cell dose was not associated with an increased risk of GVHD and had no significant influence on OS. These differences in the implications of CD34 þ cell dose for AA transplants when compared with haematological malignancies is possibly because of the unique biological nature of disease process in the former. The BM in AA is characterized by fewer haemopoietic progenitors, higher number of suppressor T cells and limited ability of mesenchymal stem cells to inhibit T-cell function. 28, 34, 35 Our study has a modest sample size in spite of performing a 10-year analysis from a national referral centre for BM failure syndromes. This is a reflection of the rarity of acquired AA as well as the fact that not all patients are treated with transplantation. Despite the size of the sample, definite adverse effects on outcome in recipients of a low stem cell dose have been identified from our analysis. Pooled multicentric data from similar institutions could provide a bigger study population with adequate statistical power. Such a multicentric study may help to further clarify the precise effects of CD34 þ cell dose on the outcome of allo-SCT for AA.
